Is BHST or IMUX more profitable?

Immunic has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. BioHarvest Sciences' return on equity of -76.03% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets BioHarvest Sciences -32.54% -76.03% -25.30% Immunic N/A -220.75% -132.04%

BioHarvest Sciences (BHST) Competitors

$1.92 -0.08 (-4.00%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.90 -0.02 (-1.04%)

As of 07/24/2026 07:34 PM Eastern

Compare

BHST vs. KROS, RNA, OTLK, IMUX, and NBP

Should you buy BioHarvest Sciences stock or one of its competitors? MarketBeat compares BioHarvest Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioHarvest Sciences include Keros Therapeutics (KROS), Avidity Biosciences (RNA), Oncobiologics (OTLK), Immunic (IMUX), and I-Mab (NBP). These companies are all part of the "pharmaceutical products" industry.

How does BioHarvest Sciences compare to Keros Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

In the previous week, Keros Therapeutics and Keros Therapeutics both had 1 articles in the media. BioHarvest Sciences' average media sentiment score of 1.89 beat Keros Therapeutics' score of 0.94 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Keros Therapeutics	Positive
BioHarvest Sciences	Very Positive

Keros Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Keros Therapeutics has higher earnings, but lower revenue than BioHarvest Sciences. Keros Therapeutics is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$33.18M	6.00	$87.01M	-$3.01	N/A
BioHarvest Sciences	$35.16M	1.07	-$11.14M	-$0.59	N/A

71.6% of Keros Therapeutics shares are held by institutional investors. 12.6% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Keros Therapeutics currently has a consensus target price of $20.40, suggesting a potential upside of 102.78%. BioHarvest Sciences has a consensus target price of $10.00, suggesting a potential upside of 420.83%. Given BioHarvest Sciences' higher probable upside, analysts clearly believe BioHarvest Sciences is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioHarvest Sciences has a net margin of -32.54% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -17.04% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

Summary

Keros Therapeutics beats BioHarvest Sciences on 9 of the 15 factors compared between the two stocks.

How does BioHarvest Sciences compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Avidity Biosciences has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

BioHarvest Sciences has a net margin of -32.54% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

In the previous week, Avidity Biosciences had 2 more articles in the media than BioHarvest Sciences. MarketBeat recorded 3 mentions for Avidity Biosciences and 1 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 1.89 beat Avidity Biosciences' score of 0.62 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Avidity Biosciences	Positive
BioHarvest Sciences	Very Positive

Avidity Biosciences currently has a consensus price target of $67.60, indicating a potential upside of 488.34%. BioHarvest Sciences has a consensus price target of $10.00, indicating a potential upside of 420.83%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than BioHarvest Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.28
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioHarvest Sciences has lower revenue, but higher earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	5.36	-$322.30M	-$0.97	N/A
BioHarvest Sciences	$35.16M	1.07	-$11.14M	-$0.59	N/A

Summary

Avidity Biosciences beats BioHarvest Sciences on 10 of the 15 factors compared between the two stocks.

How does BioHarvest Sciences compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Oncobiologics has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Oncobiologics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Oncobiologics' return on equity of 0.00% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

In the previous week, Oncobiologics had 6 more articles in the media than BioHarvest Sciences. MarketBeat recorded 7 mentions for Oncobiologics and 1 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 1.89 beat Oncobiologics' score of 0.31 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncobiologics	Neutral
BioHarvest Sciences	Very Positive

BioHarvest Sciences has higher revenue and earnings than Oncobiologics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$333.14K	626.66	-$62.42M	-$1.17	N/A
BioHarvest Sciences	$35.16M	1.07	-$11.14M	-$0.59	N/A

11.2% of Oncobiologics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Oncobiologics currently has a consensus target price of $6.50, suggesting a potential upside of 362.63%. BioHarvest Sciences has a consensus target price of $10.00, suggesting a potential upside of 420.83%. Given BioHarvest Sciences' higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than Oncobiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Oncobiologics and BioHarvest Sciences tied by winning 7 of the 14 factors compared between the two stocks.

How does BioHarvest Sciences compare to Immunic?

BioHarvest Sciences (NASDAQ:BHST) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

51.8% of Immunic shares are owned by institutional investors. 5.5% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BioHarvest Sciences currently has a consensus price target of $10.00, suggesting a potential upside of 420.83%. Immunic has a consensus price target of $47.57, suggesting a potential upside of 255.28%. Given BioHarvest Sciences' higher probable upside, research analysts plainly believe BioHarvest Sciences is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

BioHarvest Sciences has higher revenue and earnings than Immunic. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$35.16M	1.07	-$11.14M	-$0.59	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Immunic has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. BioHarvest Sciences' return on equity of -76.03% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Immunic	N/A	-220.75%	-132.04%

In the previous week, BioHarvest Sciences and BioHarvest Sciences both had 1 articles in the media. BioHarvest Sciences' average media sentiment score of 1.89 equaled Immunic'saverage media sentiment score.

Company	Overall Sentiment
BioHarvest Sciences	Very Positive
Immunic	Very Positive

BioHarvest Sciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

Summary

Immunic beats BioHarvest Sciences on 8 of the 14 factors compared between the two stocks.

How does BioHarvest Sciences compare to I-Mab?

I-Mab (NASDAQ:NBP) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

38.4% of I-Mab shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

I-Mab presently has a consensus price target of $9.00, indicating a potential upside of 408.47%. BioHarvest Sciences has a consensus price target of $10.00, indicating a potential upside of 420.83%. Given BioHarvest Sciences' higher probable upside, analysts clearly believe BioHarvest Sciences is more favorable than I-Mab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

I-Mab has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. I-Mab's return on equity of 0.00% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

In the previous week, I-Mab had 3 more articles in the media than BioHarvest Sciences. MarketBeat recorded 4 mentions for I-Mab and 1 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 1.89 beat I-Mab's score of 0.69 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
I-Mab	Positive
BioHarvest Sciences	Very Positive

I-Mab has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

BioHarvest Sciences has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	N/A	N/A	-$46.27M	-$0.36	N/A
BioHarvest Sciences	$35.16M	1.07	-$11.14M	-$0.59	N/A

Summary

I-Mab beats BioHarvest Sciences on 8 of the 13 factors compared between the two stocks.

Get BioHarvest Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHST vs. The Competition

Export

Metric	BioHarvest Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$37.66M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-3.25	21.48	27.14	23.64
Price / Sales	1.07	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	1.48	7.88	10.28	6.07
Net Income	-$11.14M	$23.86M	$3.60B	$331.99M
7 Day Performance	-28.89%	-3.82%	-1.27%	-0.63%
1 Month Performance	-30.18%	-2.61%	-0.37%	-2.00%
1 Year Performance	-74.67%	32.79%	18.30%	13.62%

BioHarvest Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHST BioHarvest Sciences	3.0196 of 5 stars	$1.92 -4.0%	$10.00 +420.8%	-75.5%	$37.66M	$35.16M	N/A	N/A	Positive News Gap Up
KROS Keros Therapeutics	2.3202 of 5 stars	$10.64 +0.3%	$20.40 +91.7%	-30.0%	$210.59M	$33.18M	N/A	100	News Coverage
RNA Avidity Biosciences	2.3711 of 5 stars	$12.15 -0.1%	$67.60 +456.4%	-65.4%	$207.84M	$36.68M	N/A	190
OTLK Oncobiologics	3.7821 of 5 stars	$1.39 -4.8%	$6.50 +367.6%	-29.8%	$206.54M	$333.14K	N/A	20	News Coverage Gap Up
IMUX Immunic	3.8623 of 5 stars	$15.16 +0.9%	$47.57 +213.8%	+25.1%	$206.49M	N/A	N/A	70	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BHST) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioHarvest Sciences (BHST) Competitors

BHST vs. KROS, RNA, OTLK, IMUX, and NBP

How does BioHarvest Sciences compare to Keros Therapeutics?

Summary

How does BioHarvest Sciences compare to Avidity Biosciences?

Summary

How does BioHarvest Sciences compare to Oncobiologics?

Summary

How does BioHarvest Sciences compare to Immunic?

Summary

How does BioHarvest Sciences compare to I-Mab?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST vs. The Competition

BioHarvest Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioHarvest Sciences (BHST) Competitors

BHST vs. KROS, RNA, OTLK, IMUX, and NBP

How does BioHarvest Sciences compare to Keros Therapeutics?

Does the media refer more to KROS or BHST?

Which has more volatility & risk, KROS or BHST?

Which has preferable earnings & valuation, KROS or BHST?

Do insiders & institutionals have more ownership in KROS or BHST?

Do analysts rate KROS or BHST?

Is KROS or BHST more profitable?

Summary

How does BioHarvest Sciences compare to Avidity Biosciences?

Which has more risk and volatility, RNA or BHST?

Is RNA or BHST more profitable?

Does the media prefer RNA or BHST?

Do analysts recommend RNA or BHST?

Which has preferable valuation and earnings, RNA or BHST?

Summary

How does BioHarvest Sciences compare to Oncobiologics?

Which has more volatility and risk, OTLK or BHST?

Is OTLK or BHST more profitable?

Does the media prefer OTLK or BHST?

Which has better valuation and earnings, OTLK or BHST?

Do institutionals & insiders have more ownership in OTLK or BHST?

Do analysts rate OTLK or BHST?

Summary

How does BioHarvest Sciences compare to Immunic?

Do institutionals and insiders hold more shares of BHST or IMUX?

Do analysts prefer BHST or IMUX?

Which has preferable earnings and valuation, BHST or IMUX?

Is BHST or IMUX more profitable?

Does the media favor BHST or IMUX?

Which has more risk and volatility, BHST or IMUX?

Summary

How does BioHarvest Sciences compare to I-Mab?

Do institutionals & insiders have more ownership in NBP or BHST?

Do analysts rate NBP or BHST?

Is NBP or BHST more profitable?

Does the media refer more to NBP or BHST?

Which has more risk and volatility, NBP or BHST?

Which has better earnings & valuation, NBP or BHST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST vs. The Competition

BioHarvest Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools